Gene Therapy for Muscular Dystrophy Faces Safety Concerns After Second Fatality
TL;DR Summary
Sarepta Therapeutics' gene therapy for muscular dystrophy, Elevidys, faced scrutiny after reports of a second death linked to acute liver injury, leading to a pause in treatment for older patients and a significant drop in stock prices, with potential regulatory implications.
- Second patient death reported with gene therapy for muscular dystrophy Yahoo Finance
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Sarepta Therapeutics
- After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry statnews.com
- Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures WSJ
- Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug Investopedia
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
90%
412 → 41 words
Want the full story? Read the original article
Read on Yahoo Finance